BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Rule of 40

The Rule of 40 of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 4.41 %. In the previous year, Rule of 40 was 28.29 % — a change of -84.40% (lower).

Rule of 40

4.41 %

YoY

-84.40%

Last updated:

Rule of 40 of BrightGene Bio-Medical Technology Co is 2025 4.41 % . Rule of 40 of BrightGene Bio-Medical Technology Co was 2024 28.29 % . It decreases by -84.40% lower compared to the previous year.

The BrightGene Bio-Medical Technology Co Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
49.94 CNY
Jan 1, 2019
48.45 CNY
Jan 1, 2020
82.61 CNY
Jan 1, 2021
60.07 CNY
Jan 1, 2022
22.68 CNY
Jan 1, 2023
37.44 CNY
Jan 1, 2024
28.29 CNY
Jan 1, 2025
4.41 CNY
The BrightGene Bio-Medical Technology Co Rule of 40 history
YEARRule of 40YoY
4.41 %-84.40%
28.29 %-24.44%
37.44 %+65.08%
22.68 %-62.24%
60.07 %-27.28%
82.61 %+70.51%
48.45 %-2.99%
49.94 %-33.86%
75.51 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Rule of 40 of BrightGene Bio-Medical Technology Co is 4.41 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co